De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Poolbeg Pharma Toekomstige groei

Future criteriumcontroles 0/6

Poolbeg Pharma's winst zal naar verwachting dalen met 12.9% per jaar. De winst per aandeel zal naar verwachting dalen met 11.7% per jaar.

Belangrijke informatie

-12.9%

Groei van de winst

-11.7%

Groei van de winst per aandeel

Pharmaceuticals winstgroei	16.3%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	18 Sep 2024

Recente toekomstige groei-updates

Geen updates

Recent updates

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Jul 12

Winst- en omzetgroeiprognoses

AIM:POLB - Toekomstschattingen van analisten en financiële gegevens uit het verleden (GBP Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2025	N/A	-6	-6	-5	2
12/31/2024	N/A	-6	-6	-6	2
6/30/2024	N/A	-4	-5	-4	N/A
3/31/2024	N/A	-4	-5	-4	N/A
12/31/2023	N/A	-4	-5	-4	N/A
9/30/2023	N/A	-4	-5	-5	N/A
6/30/2023	N/A	-5	-5	-5	N/A
3/31/2023	N/A	-5	-5	-5	N/A
12/31/2022	N/A	-5	-5	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat POLB de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat POLB de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat POLB de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van POLB naar verwachting sneller zal groeien dan de markt UK.

Hoge groei-inkomsten: Er wordt verwacht dat POLB volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van POLB naar verwachting over 3 jaar hoog zal zijn

Poolbeg Pharma Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Recent updates

Companies Like Poolbeg Pharma (LON:POLB) Are In A Position To Invest In Growth

Poolbeg Pharma Announces Voluntary Delist from OTCQB Market

Poolbeg Pharma PLC, Annual General Meeting, Jun 13, 2024

Poolbeg Pharma PLC Receives the Fully Granted Patent from the U.S. Patent Office for Its Immunomodulator II Patent Application

New minor risk - Financial data availability

Executive Chairman of The Board recently bought UK£97k worth of stock

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma plc Appoints Cathal Friel as Executive Chairman

Independent Research Confirms >$10 Billion Market Opportunity for POLB 001 as A Preventative Therapy for Cancer Immunotherapy-Induced Cytokine Release Syndrome (CRS)

Poolbeg Pharma plc Further Data Confirms Polb 001'S Potential in Cancer Immunotherapy-Induced Cytokine Release Syndrome

High number of new and inexperienced directors

Poolbeg Pharma plc Announces Positive Outputs from Lab-Based Analysis of RSV Drug Candidates Identified Using AI RSV Drug Candidates with the High Probability of Successful Successful Successfully

Poolbeg Pharma plc Announces Key Insights from Its Poster Presentation at ASH POLB 001

Poolbeg Pharma plc Announces Directorate Changes

Poolbeg Pharma plc Announces Executive Appointments

Poolbeg Pharma plc Announces Scientific Advisory Board Endorses Influenza Drug Targets Identified in Ai Drug Discovery Programme

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Favourable Conclusion of Patent Opposition

Poolbeg Pharma Receives Notice of Allowance from the Japanese Patent Office in Relation to its Immunomodulator I Patent Application

Poolbeg Pharma plc Announces Immunomodulator I Patent Opposition Withdrawal

New minor risk - Share price stability

Poolbeg Pharma plc Announces Significant Breakthrough in Its World First Influenza Artificial Intelligence Programme with Cytoreason

Less than half of directors are independent

We're Hopeful That Poolbeg Pharma (LON:POLB) Will Use Its Cash Wisely

Poolbeg Pharma PLC Announces Board Changes

Poolbeg Pharma plc Announces Strategic Expansion of Polb 001 into Oncology

Poolbeg Pharma PLC Announces Positive Initial Data Analysis in POLB 001 Trial

Poolbeg Pharma Identifies Novel RSV Drug Candidates

Poolbeg Pharma plc Announces POLB 001 LPS Human Challenge Clinical Trial Successfully Completed

Poolbeg Pharma Announces Completion of Influenza AI Model Build

Poolbeg Pharma PLC to Report First Half, 2022 Results on Sep 06, 2022

Poolbeg Pharma plc Receives Ethics and Competent Authority Approval to Commence Its Lipopolysaccharide (Lps) Human Challenge Clinical Trial for Polb 00

Here's Why We're Not Too Worried About Poolbeg Pharma's (LON:POLB) Cash Burn Situation

Poolbeg Pharma plc Provides Project Update for AI Model of RSV Data

Poolbeg Pharma PLC Provides Update on POLB 001 Clinical Development

No independent directors

Poolbeg Pharma plc Provides an Update on the Strengthening of Its Intellectual Property for Its Asset POLB 002

Poolbeg Pharma PLC to Report Q4, 2021 Results on Mar 03, 2022

Poolbeg Pharma PLC has completed an IPO in the amount of £25 million.

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven